“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
Samsung Biologics (KRX: 207940.KS) today held an online press convention to announce its goal of opening a fourth floor this year. This is a component of your long-term strategy to maximize operational power and develop your progression and production functions in reaction to the developmental demands of bioproduction. The corporation also stated that it is in negotiations with the government of IFEZ (Incheon Free Economic Zone) to acquire more land for its biological complex at the moment.
Once the terms of the trading are finalized, the total duration of the two investments is expected to be more than 2 trillion Korean won, approximately the equivalent of US$2 billion, and in the total amount invested in the company’s previous 3 plants combined in its nine. history of the year.
By adding a capacity of 256KL to your site, plant four is expected to begin production operations at the time of 2022, and the company’s position as the world’s largest single-site production facility, with a total capacity of 620KL once completed. Samsung Biologics brings a cutting-edge technique to the design strategy of its new plant: through the integration of the exclusive benefits of plants 1, 2 and 3, it will offer multi-scale production facilities to meet the varied desires of new and existing customers.
Construction will begin on an existing plant with 23.8 million square meters of total land, the equivalent of the combined land domain of its 3 existing floors. In an effort to maximize operational efficiency, Plant Four will introduce real-time production schedule simulation through newer automation and bioproduction technologies, as well as optimize the knowledge-based utility source collected at your existing plants.
Samsung Biologics is also making a strong investment to offset the environmental effect on its facilities. New complex technologies such as streamlined application, intelligent removal of high concentration wastewater and progressive nitric acid emissions will decorate the office and network environment.
The box being negotiated for Samsung Biologics’ momentary biological complex is located near the company’s existing complex and is larger with 330,000 square meters. Once the situations are complete, the company plans to create an open innovation center to inspire biotechnology corporations and build a global study and progression facility, as well as ensuring a long-term plant area in the new complex.
“In this ever-changing climate, we are strategically positioning ourselves to meet the desires of our global consumers who are generating new, more complex and diversified drugs, and providing amazing visitor satisfaction,” said Dr. Tae Han Kim, CEO of Samsung Organic. Products. “With the production of Plant 4, our ‘superfactory’, Samsung Biologics is investing in an overall refinement of its line and the addition of new amenities on a small and medium scale to achieve some production power and provide the best to raise the bar to identify us as the world’s leading standard.»
Due to its high-quality competitiveness, generation and active reaction to the demand for production of outsourced products, adding COVID-19 processing candidates, Samsung Biologics signed orders for more than 1.8 trillion Korean won, or approximately 2.5 times last year’s total sales, in the first part. 2020.
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a fully built-in CDMO that provides contract progression, production and laboratory testing services. With regulatory approvals shown, increased capacity in a singles site, and faster performance, Samsung Biologics is an award-winning selection spouse and is the only one capable of helping the progression and manufacture of biological products at each and every level of the procedure while respecting the changing desires of biopharmaceutical corporations around the world. For more information, visit www.samsungbiologics.com.
Claire Kim
82 10-3754-0880
https://samsungbiologics.com/